Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESKATA vs INNOVAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ESKATA (hydrogen peroxide) 40% topical solution deflates and scleroses mechanobullous lesions associated with seborrheic keratoses through oxidative tissue destruction.
Innovar is a combination of fentanyl (mu-opioid receptor agonist) and droperidol (butyrophenone antipsychotic that blocks dopamine D2 receptors in the CNS, producing sedation and antiemetic effects).
Treatment of raised seborrheic keratoses (SKs) with thick, scaly surfaces
Neuroleptanalgesia for surgical and diagnostic procedures,Adjunct to general anesthesia
ESKATA (hydrogen peroxide 40% topical solution) is applied topically to seborrheic keratoses using the supplied single-use applicator. Each lesion is treated once during a single office visit. The solution is applied to the lesion surface for 1 minute after puncturing the ampule. Do not repeat treatment to the same lesion within 2 weeks.
2-5 m L (droperidol 2.5-5 mg and fentanyl 0.05-0.1 mg) IM/IV every 1-2 hours as needed for neuroleptanalgesia; surgical anesthesia: initial 1 m L/10 kg IM or slow IV, then 0.5 m L increments.
Not determined; hydrogen peroxide is rapidly degraded by catalase and other peroxidases in tissues, with an estimated half-life of minutes locally.
Droperidol: terminal t1/2 2.2–2.5 h (infants 4.5 h). Fentanyl: terminal t1/2 3–7 h (mean ~4 h) in adults; prolonged in elderly (up to 16 h) and hepatic impairment.
Not systemically absorbed; degradation by catalase in tissue produces oxygen and water.
Fentanyl: CYP3A4 to norfentanyl; Droperidol: CYP3A4 and CYP1A2 to multiple metabolites.
Renal: <1% as unchanged drug; biliary/fecal: not established; hydrogen peroxide is rapidly decomposed to water and oxygen, with no significant renal or biliary excretion.
Droperidol: ~75% renal as metabolites, ~22% biliary/fecal. Fentanyl: primarily renal as metabolites (85%), ~9% fecal.
Not applicable; hydrogen peroxide is not protein bound.
Fentanyl: ~80–85% bound to albumin and α1-acid glycoprotein. Droperidol: ~85–90% bound to albumin and α1-acid glycoprotein.
Not determined for topical application; systemic absorption is minimal (<0.5% of applied dose), with Vd considered negligible.
Fentanyl: Vd 3–5 L/kg (large distribution to tissues, slow elimination). Droperidol: Vd 1.5–2 L/kg (moderate distribution).
Topical: systemic absorption <0.5% of applied dose; thus, bioavailability is negligible.
Fentanyl: IV 100%; transdermal 92% (after depot formation); transmucosal ~50% (buccal) to 70% (nasal); oral <30% due to first-pass. Droperidol: IV 100%; IM ~85% (well absorbed).
No dose adjustment is required for renal impairment. ESKATA is a topical agent with minimal systemic absorption; renal function does not affect local therapy.
e GFR >60 m L/min: no adjustment; e GFR 30-60: reduce dose by 25-50% due to fentanyl accumulation; e GFR <30: avoid or use with extreme caution, reduce dose by ≥50%, monitor for respiratory depression.
No dose adjustment is required for hepatic impairment. ESKATA is a topical agent with minimal systemic absorption; hepatic function does not affect local therapy.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated due to impaired fentanyl metabolism and increased sedation risk.
Safety and effectiveness in pediatric patients have not been established. ESKATA is not recommended for use in children.
Not FDA-approved for pediatric use; limited data: 0.1 m L/kg (droperidol 0.125 mg/kg + fentanyl 0.0025 mg/kg) IM/IV as single dose; max 1.5 m L. Contraindicated in neonates.
No specific dose adjustment is required for geriatric patients. Clinical studies included patients aged 65 years and older; no overall differences in safety or efficacy were observed compared to younger adults.
Reduce initial dose by 50-75% (e.g., 0.5-1 m L IM/IV); titrate cautiously; increased risk of hypotension, respiratory depression, and prolonged sedation; monitor renal function.
Not indicated for the treatment of seborrheic keratoses on the face, or for lesions suspected to be skin cancer.
Risk of respiratory depression, especially in elderly, debilitated, or opioid-naive patients; risk of QT prolongation and torsade de pointes with droperidol, including at recommended doses.
Do not apply to irritated or broken skin.,Avoid contact with eyes and mucous membranes.,Do not use on the face.,May cause stinging, burning, or erythema at application site.
Monitor respiratory function; avoid in patients with bradycardia, electrolyte abnormalities, or QT prolongation; risk of hypotension, neuroleptic malignant syndrome, and extrapyramidal symptoms.
Hypersensitivity to hydrogen peroxide or any component of the formulation
Hypersensitivity to fentanyl, droperidol, or components; known QT prolongation; concurrent MAOIs; severe respiratory depression; myasthenia gravis.
No known food interactions.
Avoid grapefruit juice as it may increase fentanyl levels via CYP3A4 inhibition. No specific food restrictions for droperidol. Maintain adequate hydration to prevent hypotension, but monitor for fluid overload if cardiac compromise.
No human data; pregnancy category N (not classified). In animal studies, no evidence of teratogenicity at systemic exposures up to 2.6 times the human dose. However, ESKATA contains hydrogen peroxide, which may cause oxidative injury. Risk cannot be excluded; avoid use in pregnancy.
First trimester: Risk of congenital malformations, including cardiac and neural tube defects, associated with droperidol exposure. Second and third trimesters: Risk of extrapyramidal symptoms, neuroleptic malignant syndrome, and neonatal withdrawal. Fentanyl component may cause fetal respiratory depression and intrauterine growth restriction. Use only if maternal benefit outweighs fetal risk.
No data on excretion into human milk. M/P ratio unknown. Due to potential for local irritation and systemic absorption, avoid breastfeeding during treatment or pump and discard for 24 hours after application.
Fentanyl and droperidol are excreted in breast milk. Fentanyl M/P ratio approximately 0.2–0.4. Potential for sedation and respiratory depression in the infant. Avoid breast-feeding for 24 hours after administration. Discard milk during this period.
No pharmacokinetic studies in pregnancy. Dose adjustment not recommended due to lack of data and local application; however, use only if benefit outweighs risk.
No established dose adjustments for pregnancy. Increased clearance of fentanyl in third trimester may require higher doses for analgesic effect. Lower doses of droperidol recommended due to increased volume of distribution and prolonged effects. Use lowest effective dose and monitor for excessive sedation and hypotension.
Apply with a fine-tipped applicator directly to the lesion, avoiding perilesional skin. Use a minimum amount to cover the lesion; overtreatment increases risk of local reactions. Limited to 1 treatment per lesion per visit, up to 4 lesions per session. Do not treat more than 4 lesions at a time. Lesions should be discrete, non-hyperkeratotic, and ≤1 cm in diameter.
Innovar (droperidol + fentanyl) is a neuroleptanalgesic combination; monitor for respiratory depression, hypotension, and extrapyramidal symptoms. Droperidol prolongs QTc interval; avoid in patients with electrolyte disturbances or on QT-prolonging drugs. Fentanyl is a potent mu-opioid agonist; naloxone reversal may be needed. Onset of analgesia is rapid (<2 min IV), duration 30-60 min; droperidol's sedative effect lasts 2-4 hours. Use with caution in elderly, hypovolemic, or compromised patients.
ESKATA is a topical solution applied by your healthcare provider in the office.,You may experience stinging, burning, or swelling at the application site; these effects typically resolve within days.,Do not wash or touch the treated area for at least 24 hours after application.,Avoid sun exposure on treated areas; use sunscreen and protective clothing.,Contact your provider if you experience signs of infection (increased redness, pus, fever) or severe pain.,The treated lesion may form a scab or crust which will fall off in a few weeks.,Do not apply any other creams or ointments on the treated area unless directed by your provider.,ESKATA is for external use only; avoid contact with eyes, mouth, and mucous membranes.
You may feel drowsy and lightheaded; avoid driving or operating machinery for 24 hours.,Report any difficulty breathing, slow or shallow breathing, or severe dizziness immediately.,Avoid alcohol and other sedatives while taking this medication.,Inform your doctor if you have a history of heart rhythm problems, low potassium, or low magnesium.,This drug can cause involuntary muscle movements or restlessness; notify your healthcare provider if these occur.
No interactions on record
No interactions on record
Common clinical questions about ESKATA vs INNOVAR, answered by our medical review team.
ESKATA is a Topical Keratolytic that works by ESKATA (hydrogen peroxide) 40% topical solution deflates and scleroses mechanobullous lesions associated with seborrheic keratoses through oxidative tissue destruction.. INNOVAR is a Antipsychotic (Butyrophenone) that works by Innovar is a combination of fentanyl (mu-opioid receptor agonist) and droperidol (butyrophenone antipsychotic that blocks dopamine D2 receptors in the CNS, producing sedation and antiemetic effects).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESKATA and INNOVAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESKATA is: ESKATA (hydrogen peroxide 40% topical solution) is applied topically to seborrheic keratoses using the supplied single-use applicator. Each lesion is treated once during a single office visit. The solution is applied to the lesion surface for 1 minute after puncturing the ampule. Do not repeat treatment to the same lesion within 2 weeks.. The standard adult dose of INNOVAR is: 2-5 m L (droperidol 2.5-5 mg and fentanyl 0.05-0.1 mg) IM/IV every 1-2 hours as needed for neuroleptanalgesia; surgical anesthesia: initial 1 m L/10 kg IM or slow IV, then 0.5 m L increments.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESKATA and INNOVAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESKATA is classified as Category C. No human data; pregnancy category N (not classified). In animal studies, no evidence of teratogenicity at systemic exposures up to 2.6 times the human dose. However, ESKATA contain. INNOVAR is classified as Category C. First trimester: Risk of congenital malformations, including cardiac and neural tube defects, associated with droperidol exposure. Second and third trimesters: Risk of extrapyramid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.